quinazolines has been researched along with valganciclovir in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 6 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meesing, A; Razonable, RR | 1 |
| Jung, S; Michel, D; Michel, M; Stamminger, T | 1 |
| Berney, T; Elkrief, L; Kronig, I; Neofytos, D; Van Delden, C | 1 |
| Müller, TF; Näf, B; Rho, E; Schachter, T; von Moos, S; Wüthrich, RP | 1 |
| Descourouez, JL; Garg, N; Jorgenson, MR; Mandelbrot, DA; Odorico, JS; Parajuli, S; Saddler, CM; Smith, JA | 1 |
| Garg, N; Jorgenson, MR; Kleiboeker, H; Mandelbrot, DA; Odorico, JS; Parajuli, S; Saddler, CM; Smith, JA | 1 |
| Haber, B; Limaye, AP | 1 |
| Benotmane, I; Caillard, S; Perrin, P | 1 |
1 review(s) available for quinazolines and valganciclovir
| Article | Year |
|---|---|
New Developments in the Management of Cytomegalovirus Infection After Transplantation.
Topics: Acetates; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Foscarnet; Ganciclovir; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Organ Transplantation; Quinazolines; Valganciclovir | 2018 |
7 other study(ies) available for quinazolines and valganciclovir
| Article | Year |
|---|---|
Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Hematopoietic Stem Cell Transplantation; Humans; Male; Mutation; Quinazolines; Secondary Prevention; Valganciclovir; Viral Load; Viral Proteins; Viral Structural Proteins | 2019 |
Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient.
Topics: Acetates; Allografts; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Humans; Liver; Liver Transplantation; Maintenance Chemotherapy; Off-Label Use; Postoperative Care; Quinazolines; Treatment Outcome; Valganciclovir | 2020 |
Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Kidney Transplantation; Quinazolines; Transplant Recipients; Valganciclovir | 2021 |
The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Humans; Kidney Transplantation; Quinazolines; Transplant Recipients; Valganciclovir; Viremia | 2021 |
Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Humans; Immunity, Cellular; Kidney Transplantation; Male; Quinazolines; Transplant Recipients; Valganciclovir | 2022 |
Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant-Reply.
Topics: Acetates; Antiviral Agents; Chemoprevention; Cytomegalovirus; Cytomegalovirus Infections; Kidney Transplantation; Quinazolines; Valganciclovir | 2023 |
Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant.
Topics: Acetates; Antiviral Agents; Chemoprevention; Cytomegalovirus; Kidney Transplantation; Quinazolines; Valganciclovir | 2023 |